New facility increases output, reduces cost of goods sold (COGS) and enhances service for B2B customers to address the forecasted increased demand for products

Highlights:

• Manufacturing site in Florida expands TempraMed's U.S. production footprint
• Increases capacity to meet rising demand from healthcare organizations, pharmacies, payors, and device manufacturers
• Shortens delivery timelines and improves service for customers in the United States where majority of devices have been sold to date
• Reduces COGS through localized production, improved logistics efficiency, and advanced manufacturing processes
• Opens new global markets for B2B customers, and large, global retailers
• Reinforces TempraMed's long-term commercialization strategy and supply-chain resilience

Vancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce that it has opened an additional U.S. manufacturing facility in Florida. The additional site expands the Company's operational capacity and enhances its ability to serve the rapidly growing demand for TempraMed's temperature-stable medication-storage devices across the United States and globally.

Due to anticipated B2B demand, the new facility will support high-volume production of TempraMed's core product line-including VIVI Cap™, VIVI Epi™, as well as the upcoming products, including VIVI Box™ smart-storage platform—while enabling improved delivery times, tighter quality control, and increased supply-chain flexibility. By localizing production within the U.S., the Company is also positioned to meaningfully reduce cost of goods sold (COGS) through streamlined logistics, reduced import dependencies, and optimized manufacturing workflows.

"Opening a new manufacturing site marks a major step in strengthening our U.S. presence and ensuring we can meet the accelerating needs of healthcare providers, pharmacies, payors, and strategic partners," said Ron Nagar, CEO of TempraMed. "Domestic manufacturing gives us the scale, speed, and reliability required to support some of the fastest-growing segments in temperature-sensitive medicine—including GLP-1 therapies, biologics, and self-injectables. It also directly supports our commitment to deliver high-quality, cost-effective solutions that protect patients, reduce waste, and ease the operational burden on health systems."

The new site will operate alongside TempraMed's existing global manufacturing network, providing redundancy, efficiency, and a scalable platform for future product introductions. The Company anticipates continued growth in B2B demand as medication manufacturers, distributors, and healthcare systems adopt new standards for in-home and point-of-care temperature management.

"Expanding our U.S. manufacturing footprint strengthens every part of our business—commercialization, cost structure, and customer satisfaction," added Nagar. "It positions TempraMed to become the preferred partner for organizations seeking robust, compliant, and sustainable solutions for protecting high-value medications."

About TempraMed Technologies Ltd.

TempraMed Technologies Ltd. is a global leader in innovative, temperature-controlled medication storage solutions. Founded with the mission to safeguard the effectiveness of life-saving medications, TempraMed develops patented, FDA-registered, space-grade thermal insulation devices that work 24/7 without batteries or external power. With a proven product line including VIVI Cap and VIVI Epi, and a smart technology platform on the horizon, TempraMed enables patients and healthcare providers to confidently manage temperature-sensitive medications anywhere, anytime. Headquartered in Israel with operations in North America, Europe, and Asia, TempraMed is advancing the future of medication protection and adherence.

Cautionary Statements

This press release contains "forward-looking statements or information." Forward-looking statements can be identified by words such as: anticipate, intend, plan, goal, seek, believe, project, estimate, expect, strategy, future, likely, may, should, will and similar references to future periods. Examples of forward-looking statements in this press release include statements made regarding information about future plans, expectations and objectives of the Company overall.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. The Company may not actually achieve its plans, projections, or expectations. The forward-looking statements and information are based on certain key expectations and assumptions made by the Company. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: the adequacy of our cash flow and earnings, the availability of future financing and/or credit, developments and changes in laws and regulations, consumer sentiment towards the Company's products, failure of counterparties to perform their contractual obligations, government regulations, competition, loss of key employees and consultants, and general economic, market or business conditions, the impact of technology and social changes on the products and industry.

Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. Except as required by applicable securities laws, we undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/278378